Hope Biosciences Research Foundation Reports Promising Phase II …
2024年10月31日 · SUGAR LAND, TX, USA I October 31, 2024 I Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) today shares positive top-line results of a Phase II clinical trial to evaluate Hope Biosciences’ adipose‑derived autologous mesenchymal stem cell therapy (HB-adMSCs) for patients with mild to moderate relapsing remitting multiple sclerosis (MS), a disease ...
ESSENCE Phase 3 trial results demonstrating statistically significant ...
2024年11月20日 · The trial achieved both its primary endpoints, with semaglutide 2.4 mg demonstrating statistically significant and superior improvements in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH compared to placebo. 1 Supportive secondary endpoints showed improvements in liver enzymes, including ...
PeptiDream Announces Second Internal Peptide …
2024年12月14日 · KAWASAKI, Japan I December 12, 2024 I PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo:4587) today announced its second wholly-owned peptide radiopharmaceutical development candidate arising from the company’s ongoing internal peptide radiopharmaceutical discovery and development efforts.
City Therapeutics Launches with $135 Million Series A Financing to …
2024年10月9日 · Harnessing next-generation siRNA engineering to improve and expand the therapeutic reach of RNAi-based medicines. Building sustainable product engine for innovative RNAi therapeutics to make a significant impact for patients across multiple disease indications, with first program expected to enter clinical development at or around year-end 2025
REGENXBIO Presents Positive Data from the Phase II Study of …
2024年10月21日 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Duality Biologics and GSK Enter Exclusive Option Agreement for a …
2024年12月4日 · PRINCETON, NJ, USA I SHANGHAI and SUZHOU, China I December 3, 2024 I Duality Biologics (“DualityBio”), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjugate (ADC) therapeutics, today announced that it has entered into an exclusive option agreement with GSK for a potentially best-in-class ADC candidate, DB-1324.
Nimbus Therapeutics Presents First Preclinical Data on Novel WRN ...
2024年10月24日 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Expression Therapeutics Announces Promising Phase 1 Results for ...
ATLANTA, GA, USA I December 11, 2024 I Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral vector-based gene therapy — ET3 — for hemophilia A at the Annual Meeting of the American Society of Hematology (ASH) in San Diego, California. The results of the study, “Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A ...
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for …
2024年10月12日 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a …
2024年10月12日 · Dong-A ST’s biologics license application (BLA) for Imuldosa, submitted in October 2023, is approved by the U.S. Food and Drug Administration